Asset Details
Do you wish to reserve the book?
Subnetwork-based prognostic biomarkers exhibit performance and robustness superior to gene-based biomarkers in breast cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Subnetwork-based prognostic biomarkers exhibit performance and robustness superior to gene-based biomarkers in breast cancer
Do you wish to request the book?
Subnetwork-based prognostic biomarkers exhibit performance and robustness superior to gene-based biomarkers in breast cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
Subnetwork-based prognostic biomarkers exhibit performance and robustness superior to gene-based biomarkers in breast cancer
2018
Overview
Background: Effective classification of cancer patients into groups with differential survival remains an important and unsolved challenge. Biomarkers have been developed based on mRNA abundance data, but their replicability and clinical utility is modest. Integrating functional information, such as pathway data, has been suggested to improve biomarker performance. To date, however, the advantages of subnetwork-based biomarkers have not been quantified. Results: We deeply sampled the population of prognostic gene-based and subnetwork-based biomarkers in a breast cancer meta-dataset of 4,960 patients. Analysing the performance and robustness of 22,000,000 gene biomarkers and 6,250,000 subnetwork biomarkers across twenty different training:testing cohort partitions of the meta-dataset revealed that subnetwork biomarkers exhibit superior overall performance and higher concordance across partitions. We find evidence of an upper bound for optimal biomarker size of ~200 genes or ~100 subnetworks. Additionally, with both biomarker feature types, larger biomarkers tend to show less consistency in performance across partitions, suggestive of over-fitting. Finally, an evaluation of varying training cohort sizes quantifies the effects of training cohort size. Conclusions: Many groups are developing techniques for exploiting network-based representations of biological pathways to characterize cancer and other diseases. By considering the distribution of gene- and subnetwork-based biomarkers, we show that pathway data improves performance and replicability, and that smaller biomarkers are more robust across patient cohorts. These insights may facilitate development of clinically useful biomarkers.
Publisher
Cold Spring Harbor Laboratory Press,Cold Spring Harbor Laboratory
Subject
